Ahead of U.S. midterm elections, the Healthcare Financial Management Association (HFMA) called for cross-sector action on healthcare affordability and urged financial leaders to sign its Declaration on Healthcare Affordability and Sustainability. The group framed the issue as a political and operational priority tied to rising costs and the need to move beyond blame-centered approaches. While not a drug development event, the policy signal matters to biotech because affordability pressures increasingly influence payer coverage decisions, utilization management strategies, and budget allocations for high-cost therapies. The message from HFMA suggests that reimbursement and access discussions are likely to intensify around measurable cost sustainability commitments—creating additional downstream variables for adoption of novel therapeutics.